Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution

Elizabeth A. Griffiths; Brahm H. Segal

doi:10.1016/j.ccell.2021.07.001

Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution

Elizabeth A. Griffiths
, Brahm H. Segal

Office of Research Compliance

Roswell Park Cancer Institute

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

SARS-CoV-2 vaccines are effective in preventing COVID-19. Patients with cancer are at high risk for severe COVID-19 and are appropriately prioritized for vaccination. Several studies in this issue of Cancer Cell add to our knowledge of the heterogeneity of immune responses to vaccination among patients with cancer and identify important areas for future research.

Original language	English
Pages (from-to)	1045-1047
Number of pages	3
Journal	Cancer Cell
Volume	39
Issue number	8
DOIs	https://doi.org/10.1016/j.ccell.2021.07.001
State	Published - Aug 9 2021

Access to Document

10.1016/j.ccell.2021.07.001

Cite this

@article{b3037af518b84100acd48ef3b842bb10,

title = "Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution",

abstract = "SARS-CoV-2 vaccines are effective in preventing COVID-19. Patients with cancer are at high risk for severe COVID-19 and are appropriately prioritized for vaccination. Several studies in this issue of Cancer Cell add to our knowledge of the heterogeneity of immune responses to vaccination among patients with cancer and identify important areas for future research.",

author = "Griffiths, \{Elizabeth A.\} and Segal, \{Brahm H.\}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = aug,

day = "9",

doi = "10.1016/j.ccell.2021.07.001",

language = "English",

volume = "39",

pages = "1045--1047",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - Immune responses to COVID-19 vaccines in patients with cancer

T2 - Promising results and a note of caution

AU - Griffiths, Elizabeth A.

AU - Segal, Brahm H.

PY - 2021/8/9

Y1 - 2021/8/9

N2 - SARS-CoV-2 vaccines are effective in preventing COVID-19. Patients with cancer are at high risk for severe COVID-19 and are appropriately prioritized for vaccination. Several studies in this issue of Cancer Cell add to our knowledge of the heterogeneity of immune responses to vaccination among patients with cancer and identify important areas for future research.

AB - SARS-CoV-2 vaccines are effective in preventing COVID-19. Patients with cancer are at high risk for severe COVID-19 and are appropriately prioritized for vaccination. Several studies in this issue of Cancer Cell add to our knowledge of the heterogeneity of immune responses to vaccination among patients with cancer and identify important areas for future research.

UR - https://www.scopus.com/pages/publications/85109641204

U2 - 10.1016/j.ccell.2021.07.001

DO - 10.1016/j.ccell.2021.07.001

M3 - Article

C2 - 34242573

AN - SCOPUS:85109641204

SN - 1535-6108

VL - 39

SP - 1045

EP - 1047

JO - Cancer Cell

JF - Cancer Cell

IS - 8

ER -

Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution

Abstract

Access to Document

Other files and links

Fingerprint

Cite this